ZENAS BIOPHARMA

Trademark usage description

pharmaceutical preparations in the nature of auto-immune and immune-based therapies for the treatment of autoimmune diseases; pharmaceutical preparati Read More

Classification Information

Class [005]
Pharmaceutical preparations in the nature of auto-immune and immune-based therapies for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune and immune-based diseases.

Classification kind code

Class [042]
Pharmaceutical development services; scientific and medical research services; pharmaceutical development services, namely, development of auto-immune and immune-based therapies.

Classification kind code

Mark Details

Serial Number

2391506

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 257 on 10^th Apr 2025	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 9^th Apr 2025	Created
Submitted for opposition 31 on 9^th Apr 2025	Formalized
Submitted for opposition 228 on 14^th Feb 2025	International Registration
Submitted for opposition 30 on 14^th Feb 2025	Filed

ZENAS BIOPHARMA

Classification Information

Class [005]Pharmaceutical preparations in the nature of auto-immune and immune-based therapies for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune and immune-based diseases.

Classification kind code

Class [042]Pharmaceutical development services; scientific and medical research services; pharmaceutical development services, namely, development of auto-immune and immune-based therapies.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations in the nature of auto-immune and immune-based therapies for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune and immune-based diseases.

Class [042]
Pharmaceutical development services; scientific and medical research services; pharmaceutical development services, namely, development of auto-immune and immune-based therapies.